恶性肿瘤患者治疗前后血浆纤维蛋白原含量分析

Analysis on the changes of plasma fibrinogen(FIB) content in malignant tumor patients before and after treatment

目的观察恶性肿瘤患者治疗前后血浆纤维蛋白原(FIB)含量与抗肿瘤治疗疗效的关系。方法采用全自动血凝分析仪测定188例恶性肿瘤患者治疗前后血浆FIB含量,115例健康体检者为对照。结果恶性肿瘤组FIB含量(5.05±1.12)g/L较健康体检组(2.91±0.87g/L)显著升高(P<0.01)。临床Ⅲ、Ⅳ期患者FIB含量(5.13±1.48g/L)显著高于Ⅰ、Ⅱ期(4.62±1.26g/L)的患者(P<0.05)。治疗后有效的患者FIB含量(2.92±1.33g/L)较治疗前(4.85±1.36g/L)显著下降(P<0.01)。无效者治疗前FIB含量(5.41±1.05g/L)与治疗后(4.85±1.26g/L,)比较无显著变化(P>0.05)。结论血浆FIB含量在恶性肿瘤的辅助诊断、疗效判断及预后评估方面有一定临床意义。

Objective To investigate the relation between the curative effect and the changes of plasma fibrinogen（FIB） content in malignant tumor patients before and after treatment. Methods Automated coagulation analyzer was used to measure the FIB content in 188 cases of malignant tumor patients before and after treatment. 115 cases healthy medical checkup people was compared. Results The FIB content of the malignant tumor patients was significantly higher than that of the healthy persons（ P 〈 0.01 ） . The FIB content of patients in stage Ⅲ and Ⅳ was higher than that in stage Ⅰ and Ⅱ （ P 〈 0.05） . The FIB content decreased significantly in patients with curative effect （ P 〈 0.01 ） , but the FIB content in patients without effect didn＇ t change （ P 〉 0.05） . Conclusion The FIB plays an important role in the diagnosis , evaluation of therapeutic effect and prognosis of malignant tumor patients.